

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

1/1	atg aga att tcg aaa cca cat ttg aga agt att tcc atc cag tgc tac ttg tgt tta ctt	31/11
Met arg ile ser lys pro his leu arg ser	ile ser ile gin cys tyr leu cys leu leu	
61/21	cta aac agt cat ttt cta act gaa gct ggc att cat gtc ttc att ttg ggc tgt ttc agt	91/31
leu asn ser his phe leu thr glu ala gly	ile his val phe ile leu gly cys phe ser	
121/41	gca ggg ctt cct aaa aca gaa gcc aac tgg gtg aat gta ata agt gat ttg aaa aaa att	151/51
ala gly leu pro lys thr glu ala asn trp val	asn val ile ser asp leu lys lys ile	
181/61	gaa gat ctt att caa tct atg cat att gat gct act tta tat acg gaa agt gat gtt cac	211/71
glu asp leu ile gln ser met his ile asp ala thr leu tyr thr glu ser asp val his		
241/81	ccc agt tgc aaa gta aca gca atg aag tgc ttt ctc ttg gag tta caa gtt att tca ctt	271/91
pro ser cys lys val thr ala met lys cys phe leu leu glu leu gln val ile ser leu		
301/101	gag tcc gga gat gca agt att cat gat aca gta gaa aat ctg atc atc cta gca aac aac	331/111
glu ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn		
361/121	agt ttg tct tct aat ggg aat gta aca gaa tct gga tgc aaa gaa tgt gag gaa ctg gag	391/131
ser leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu glu glu		
421/141	gaa aaa aat att aaa gaa ttt ttg gac agt ttt gta cat att gtc gac atg ttc atc aac	451/151
glu lys asn ile lys glu phe leu asp ser phe val his ile val asp met phe ile asn		
481/161	act tct tga (SEQ ID NO:1)	
thr ser opa (SEQ ID NO:2)		

FIG. 1

DNA sequence 489 b.p. atgagaatttcg ... aacacttcttga linear

1/1	atg aga att tcg aaa cca cat ttg aga agt att tcc atc cag tgc tac ttg tgt tta ctt	31/11
Met	arg ile ser lys pro his leu arg ser ile ser ile gin cys tyr leu cys leu leu	
61/21	cta aac agt cat ttt cta act gaa gct ggc att cat gtc ttc att ttg ggc tgt ttc agt	91/31
leu	asn ser his phe leu thr glu ala gly ile his val phe ile leu gly cys phe ser	
121/41	gca ggg ctt cct aaa aca gaa gcc aac tgg gtg aat gta ata agt gat ttg aaa aaa att	151/51
ala	gly leu pro lys thr glu ala asn trp val asn val ile ser asp leu lys lys ile	
181/61	gaa gat ctt att caa tct atg cat att gat gct act tta tat acg gaa agt gat gtt cac	211/71
glu	asp leu ile gln ser met his ile asp ala thr leu tyr thr glu ser asp val his	
241/81	ccc agt tgc aaa gta aca gca atg aag tgc ttt ctc ttg gag tta caa gtt att tca ctt	271/91
pro	ser cys lys val thr ala met lys cys phe leu leu glu leu gln val ile ser leu	
301/101	gag tcc gga gat gca agt att cat gat aca gta gaa aat ctg atc atc gca aac aac	331/111
glu	ser gly asp ala ser ile his asp thr val glu asn leu ile ile leu ala asn asn	
361/121	tct tct aat ggg aat gta aca gaa tct gga tgc aaa gaa tgt gag gaa ctg gag	391/131
ser	leu ser ser asn gly asn val thr glu ser gly cys lys glu cys glu leu glu	
421/141	gaa aaa aat att aaa gaa ttt ttg cag agt ttt gta cat att gtc caa atg ttc atc aac	451/151
glu	lys asn ile lys glu phe leu gln ser phe val his ile val gln met phe ile asn	
431/161	act tct tga (SEQ ID NO:3)	
thr	ser opa (SEQ ID NO:4)	

FIG. 2




FIG. 3A




FIG. 3B





FIG. 3C






FIG. 4A




FIG. 4B




FIG. 4C




FIG. 5B




FIG. 5A




FIG. 5C




FIG. 5D






FIG. 5E



Treatment

FIG. 6



Fluorescence Intensity of FcRI/CHO

FIG. 7




FIG. 8




FIG. 9




FIG. 10

Treatment	1° Allograft Function	MST of Functioning Grafts	n
no-Treatment	40%	6	7
Rapamycin*	50%	12	6
MR1+CTLA4/Fc+ Rapamycin**	75%	30	4
Lytic IL-2/Fc+mIL-15/Fc+ Rapamycin***	100%	>110	5
Non-lytic IL-2/Fc+mIL-15/Fc 50% +Rapamycin***		16	4

- * Rapamycin treatment was initiated 7 day prior to transplantation with 3 mg/kg i.p. daily for 7 days and continued every other day for 4 wks. . DBA2 mice were used as islet allograft donors.
 ** MR1 treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administered on day -7, -5, -3, 0 to transplantation at a dose of 0.2 mg i.p. .
 *** IL-2/Fc, and mutant IL-15/Fc treatment was initiated 7 day prior to transplantation for 4 weeks. IL-2/Fc and mutant IL-15/Fc treatment was given at a dose of 5 µg i.p. daily for 4 weeks.

FIG. 11

Tr atment	MST of Functioning Grafts	n
no-Treatment	15	4
Rapamycin*	17	4
Rapamycin + MR1+CTLA4/Fc**	25	4
Rapamycin + Lytic IL-2/Fc ***	22	4
Rapamycin + Lytic mutant IL-15/Fc ***	18	3
Rapamycin + Lytic IL-2/Fc+ mutant IL-15/Fc ***	>60	6

* Rapamycin treatment was initiated at the day of transplantation with 3 mg/kg i.p daily for 7 days and continued every other day for 4 wks. DBA2 mice were used as skin allograft donors.
** MR1 treatment was administrated on day 0, 2, 4, 6 to transplantation at a dose of 0.25 mg i.p. . CTLA4/Fc treatment was administrated on day 0, 2, 4, 6 to transplantation at a dose of 0.2 mg i.p. .
*** IL-2/Fc, and mutant IL-15/Fc treatment was initiated on the day of transplantation with a dose of 5 µg i.p. daily for 4 weeks.

FIG. 12




FIG. 13